ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.93
-0.04 (-0.40%)
At close: Dec 5, 2025, 4:00 PM EST
9.62
-0.31 (-3.12%)
After-hours: Dec 5, 2025, 5:01 PM EST
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for ARS Pharmaceuticals stock ranges from a low of $27 to a high of $40. The average analyst price target of $31.25 forecasts a 214.70% increase in the stock price over the next year.
Price Target: $31.25 (+214.70%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 4, 2025.
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +302.82% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +202.11% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +181.97% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +171.90% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +202.11% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
82.31M
from 89.15M
Decreased by -7.67%
Revenue Next Year
241.29M
from 82.31M
Increased by 193.13%
EPS This Year
-1.68
from 0.08
EPS Next Year
-0.80
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 92.1M | 276.4M | ||||
| Avg | 82.3M | 241.3M | ||||
| Low | 73.5M | 211.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.3% | 235.8% | ||||
| Avg | -7.7% | 193.1% | ||||
| Low | -17.6% | 156.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.46 | -0.18 | ||||
| Avg | -1.68 | -0.80 | ||||
| Low | -1.88 | -1.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.